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Abstract
Purpose: One way of evaluating family history (FH) for classifying BRCA1/2 variants of uncertain clinical significance
(VUS) is to assess the “BRCA-ness” of a pedigree by comparing it to reference populations. The aim of this study
was to assess if prediction of BRCA pathogenic variant (mutation) status based on pedigree information differed
due to changes in FH since intake, both in families with a pathogenic variant (BRCAm) and in families with
wild-type (BRCAwt).
Patients and methods: We compared the BRCA1/2 pathogenic variant detection probabilities between intake
and most recent pedigree for BRCAm families (n = 64) and BRCAwt (n = 118) using the BRCAPRO software program.
Results: Follow-up time between intake and most recent pedigree was significantly longer (p < 0.001) in the BRCAm
compared to the BRCAwt families.
Among BRCAwt families, the probability to detect a pathogenic variant did not change over time. Conversely, among
the BRCAm, this probability was significantly higher for most recent vs. intake pedigree (p = 0.006).
Conclusion: Clinical scores change significantly over time for BRCAm families. This may be due to differences in
follow-up, but also to differences in cancer risks from carrying a pathogenic variant in a highly penetrant gene.
To reduce bias, models for VUS classification should incorporate FH collected at intake.
Keywords: BRCA1/2, Variant classification models, Family history, Variants of uncertain clinical significance, Intake
pedigrees
Introduction
A significant fraction of BRCA1/2 gene analyses result
in the detection of a genetic variant for which the
pathogenicity is unknown. These variants are named
“variants of uncertain clinical significance” (VUS). VUS
results occur in approximately 5–15 % of BRCA1/2
sequencing tests with the likelihood dependent on the
patient’s racial or ethnic background [1]. At the moment,
ENIGMA (Evidence-based Network for the Interpretation
of Germline Mutant Alleles; www.enigmaconsortium.org)
has received >6000 submissions of BRCA1/2 VUS corre-
sponding to >3000 individual variants.
Different approaches have been suggested to deter-
mine the pathogenicity of VUS. Pedigree information is
routinely used in the clinical setting to estimate the
probability of finding a pathogenic variant in BRCA1/2,
and thereby guide clinical testing. Hence pedigree infor-
mation has utility to assess if a variant carrier portrays
the features expected for an individual carrying a patho-
genic variant (mutation) in BRCA1/2. Pathogenic variant
probability scores can be obtained using existing soft-
ware programs such as BOADICEA [2, 3], BRCAPRO
[4, 5], Myriad [6, 7] or the Manchester scoring system
[8] that measure how “BRCA-like” personal/family his-
tory is for a proband. Previously, we demonstrated that
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BRCAPRO scores can be used to predict the probability
of a certain VUS being a pathogenic or a neutral variant
in an analysis of a single cohort with defined selection
criteria for BRCA1/2 testing [9, 10]. Others have devel-
oped custom descriptions of family history, from a
largely unselected patient group, for use in BRCA vari-
ant classification [11, 12].
A major advance in classifying VUS in BRCA1/2 is
the multifactorial probability-based model that was de-
veloped in 2004 [13], and has been extensively reviewed
and updated ever since [11, 14]. Personal and cancer
family history associated with the VUS is a strong com-
ponent for this model [11]. An important question to
address is the possibility of bias for pedigree informa-
tion collected in the familial cancer setting, where re-
cords of family history change over time. Specifically in
the families with a pathogenic variant, there is potential
for more intensive follow-up and recording of family
history due to cascade testing of relatives and ongoing
surveillance of positive and at-risk family members.
Since it is not standard practice in the Genetics centers
to keep the intake pedigrees, such bias, if it exists,
would have implications for the value of family history
information for use in variant classification. The aim of
our study was to establish if there are significant differ-
ences between mutation probability scores of intake
and current pedigrees, if the extent of these differences
is markedly altered between carriers of pathogenic vari-
ants versus non-carriers, and which parameters might
account for such a difference. Our hypothesis was that,
if calculations are restricted to the proband’s first and
second degree relatives’ cancer history, information will




Our study population consisted of probands that con-
sulted the department of Clinical Genetics of Maastricht
University Medical Centre between 2009 and 2013 and
underwent complete BRCA1 and BRCA2 analysis. Eligi-
bility criteria remained the same in this period of time
and were those used in the Netherlands for referral to a
Genetics center [15]. All consecutive probands in whom
a pathogenic variant was found were included for the
positive control group. For the negative control group
we collected twice as many probands, randomly selected
by the last figure of the study number.
Intake pedigrees of all probands had been obtained
and kept. Intake pedigrees are those made at the first
proband’s visit containing information upon which deci-
sion to perform DNA-testing was made. The date of the
intake pedigree and the date of the last update (i.e. the
most recent pedigree) were annotated.
Clinical data
The probability to detect a pathogenic variant, measured
as the BRCAPRO score, was our primary outcome meas-
ure. It was retrospectively obtained for all the included
probands. The BRCAPRO model is distributed as a part
of the counseling package CancerGene from U.T. South-
western Medical Center at Dallas [3, 11]. BRCAPRO is a
model that incorporates pathogenic variant frequencies
and cancer-specific penetrances, in addition to clinical
information about the proband and the first-degree and
second-degree relatives, and with this estimates the prob-
ability of finding a pathogenic variant [4, 5]. For every
proband, the BRCAPRO score based on the intake pedi-
gree was obtained. If there had been any changes in the
pedigree over time, the BRCAPRO score based on the
most recent pedigree was also obtained.
Laboratory diagnosis
BRCA1 and BRCA2 were analyzed from blood samples
by denaturing high-performance liquid chromatography.
Changes in denaturing high-performance liquid chroma-
tography were verified by standard sequence analysis. To
detect large duplications or deletions in BRCA1, multi-
plex ligation-dependent probe amplification analysis was
also performed.
Statistical analysis
Descriptive analysis was performed for the group with
wt BRCA and the group with a pathogenic variant. The
differences between the group with wt BRCA and the
group with a pathogenic variant, and the differences be-
tween the intake and the most recent pedigree, were
obtained with the t test for the continuous variables,
the Poisson log-linear regression model for the discrete
variables (e.g. number of patients with breast cancer),
and the Fisher’s exact test for binary variables which
were set up as two-by-two tables.
Results
Sixty-four probands with a pathogenic variation in BRCA1
(N = 35) or BRCA2 (N = 29) and 118 probands with wt
BRCA1/2 were included. Follow-up time between the date
of the intake pedigree and the date of the last update
was significantly longer (p < 0.001) for families with a
pathogenic variant compared to families with wt BRCA
(580 days ± 364 vs. 127 days ± 153 respectively).
The clinical features of both groups are displayed in
Table 1.
The BRCAPRO score, probability of BRCA1/2 patho-
genic variant detection, was significantly higher for the
families with a pathogenic variant compared to families
with wt BRCA: based both on the intake pedigree and
on the most recent pedigree (p < 0.001). No significant
differences were observed with regard to gender, age of
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onset of the first tumor, and type of cancer of the pro-
bands or in the families (Table 1).
Comparison of the pedigrees (intake versus recent) in
families with a pathogenic variant (Table 2) showed that
the BRCAPRO pathogenic variant detection probability
was significantly higher (p = 0.006) when based on the
most recent pedigree (0.505 ± 0.327) than on the intake
pedigree (0.442 ± 0.306).
Further analysis of the separate components of the
BRCAPRO model showed that frequencies from each of
the parameters were higher in the recent pedigree, al-
though only the increased number of patients with both
breast and ovarian cancer reached statistical significance
(mean ± SD, intake 0.09 ± 0.294, recent 0.16 ± 0.366, p =
0.007). Four females who developed both breast and
ovarian cancer accounted for this difference. In two of
them there were new events, one had already occurred
before the intake but was not known to the index, and
for the fourth case the date of diagnosis was unknown
and therefore could not be distinguished if it was either
a new or an unreported event. Conversely, the patho-
genic variant detection probability in the wt families did
not change significantly over time (Table 2).
In order to investigate the relative contributions of lon-
ger follow-up vs. higher cancer risks in the BRCAPRO
scores of the most recent BRCAm pedigrees, we looked at
the BRCAPRO scores of the BRCAm families to identify
those which have changed with time, using the mean
follow-up of the wild type families: 127 days as cut-off
point. The comparison of the BRCAPROs between intake
(0.443 ± 0.306) and follow-up at 127 days, (0.462 ± 0.311)
showed no statistically significant difference (p = 0.168).
Therefore differences occur after 127 days. Secondly,when
comparing the most recent BRCAPRO scores of the wt
families (0.290 ± 0.242) with the BRCAPRO scores of the
BRCAm families at 127 days (0.462 ± 0.311) the difference
remains statistically significant (p < 0.001).
Discussion
In the current study we show that the pathogenic vari-
ant detection probability based on pedigree information
Table 1 Clinical features of families with breast and/or ovarian
cancer: wild type (wt) vs. pathogenic variant (mutation; BRCAm)
BRCA wt BRCAm
N = 118 N = 64
Mean ± SD Mean ± SD P
Proband data
BRCAPRO score totala
Intake pedigree 0.281 ± 0.239 0.442 ± 0.306 <0.001
Recent pedigree 0.290 ± 0.242 0.505 ± 0.327 <0.001
Age of onset of first cancera
(in years)
46.27 ± 11.695 43.84 ± 11.776 0.197
Percentage Percentage
Sex (female)b 96.6 100 0.299
BCb 81.4 81.3 1.000
OCb 6.8 7.8 0.772
BC and OCb 3.4 6.2 0.455
Healthyb 8.5 4.7 0.548
Family datac Meane Meane
No. of patients in each
pedigree with
BCd 2.31 2.34 0.883
OCd 0.28 0.31 0.730
BC and OCd 0.06 0.09 0.392
Bilateral BCd 0.42 0.42 0.985
BC in mend 0.04 0.06 0.551
aUnivariate Gaussian linear regression model (t-test). bTwo-by-two table
(Fisher’s exact test). cBased on intake pedigree. dPoisson log-linear regression
model. eStandard errors are in log scale, not shown
Table 2 Clinical features from the intake versus most recent pedigrees in families with BRCAwt and in families with BRCAm
BRCA genotype families BRCA wild type
(n = 118)
BRCA pathogenic variant (mutation)
(n = 64)
Intake pedigree Recent pedigree Intake pedigree Recent pedigree
Mean ± SD Mean ± SD p Mean ± SD Mean ± SD p
BRCAPRO score totala 0.281 ± 0.239 0.290 ± 0.242 0.339 0.442 ± 0.306 0.505 ± 0.327 0.006
BRCAPRO 1 scorea 0.160 ± 0.159 0.168 ± 0.170 0.263 0.295 ± 0.227 0.341 ± 0.256 0.005
BRCAPRO 2 scorea 0.121 ± 0.119 0.121 ± 0.117 0.907 0.147 ± 0.175 0.162 ± 0.184 0.151
No. of patients with: Meanc Meanc Meanc Meanc
BCb 2.31 2.31 0.746 2.34 2.36 0.636
OCb 0.28 0.32 0.153 0.31 0.33 0.165
BC and OCb 0.06 0.06 0.09 0.16 0.007
Bilateral BCb 0.42 0.43 0.415 0.42 0.47 0.169
BC in menb 0.04 0.04 0.06 0.08 0.161
aPaired t-test. bPoisson log-linear regression model. cStandard errors are in log scale, not shown
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increases significantly over time in families with a patho-
genic variant, in contrast to families with wt BRCA. In
particular, the number of women with both breast and
ovarian cancer was significantly higher in the most recent
pedigree. This indicates that, even if analyses are restricted
to cancer history in first and second degree relatives,
potential for bias needs to be considered when using fam-
ily history information for the purposes of BRCA variant
classification.
As expected, the mean BRCAPRO score was signifi-
cantly higher in families with a pathogenic variant com-
pared to wt families. This underscores the ability of the
BRCAPRO model to distinguish between these two
groups and is consistent with the results of previously
published studies [5, 9, 10, 16]. A recent study from
Germany including 7352 families confirmed that, com-
pared with other risk prediction models, BRCAPRO
and BOADICEA have the highest ability to discriminate
between pathogenic variant carriers and non-carriers
[16]. We specifically selected BRCApro over other pos-
sible tools since: (i) we hypothesized that potential bias
between BRCA positive and negative pedigrees would
be minimized since this tool only collects information
on 1st and 2nd degree relatives; (ii) it was readily available
in our clinic, and there was considerable user experience.
The follow-up time, i.e. the time between the date of
the intake pedigree and the date of the last update was
significantly longer in families with a pathogenic variant
than in wt families, which is one of the factors that
explains why pathogenic variant detection probabilities
were different between the most recent and the intake
pedigree in families with a pathogenic variant, as opposed
to pedigrees with wt BRCA. This is in accordance with the
fact that relatives from families with a pathogenic BRCA
variant are offered predictive testing, which results in
updating of pedigrees with newer or more accurate infor-
mation. In contrast, relatives of probands with wt BRCA
generally do not visit the genetics department and their
pedigrees are not updated. The 127 days that on average
had passed between intake and recent pedigree for wt
families can largely be explained by the time that was
needed for DNA testing and the time expended to obtain
medical information from relatives.
In addition to longer follow-up, another factor contrib-
uting to the significant increase in pathogenic variant
probabilities in the most recent pedigrees in the BRCA
mutation group can be the underlying genetic cause, i.e.
having a high penetrant cancer risk variant as opposed to
the BRCA wt sequence families. The effect of the under-
lying genetic cause is shown by the fact that at the intake
there was already a significant difference between both
groups, and that this difference remained significant when
comparing the groups at the shorter mean follow-up time
observed for BRCA wt sequence families.
In conclusion, in this study we show that the BRCA
pathogenic variant probability scores calculated in pedi-
grees from families with a pathogenic variant change over
time, while pedigrees of wt families are less often updated
and do not significantly change over time. These findings
indicate that there is potential for bias which should be
taken into account when using family history information
in statistical models that assess the pathogenicity of BRCA
variants, and possibly other high-risk cancer predispos-
ition genes. We suggest that the simplest solution to avoid
bias would be to use only information from intake pedi-
grees, or when these are not available, to exclude from
analyses all cancer events that have occurred after the date
of the intake.
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